<DOC>
	<DOC>NCT01927263</DOC>
	<brief_summary>The purpose of this study is to investigate similarity between NI-071 and infliximab(the comparator) in terms of efficacy in patients with Rheumatoid Arthritis not adequately responding to Methotrexate.</brief_summary>
	<brief_title>A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>1. Patients with a diagnosis of RA as defined by the American College Rheumatology (ACR) and European League Against Rheumatism (EULAR) criteria (ACR/EULAR 2010) 2. Patients who received MTX treatment (6 16mg/week) for 2 weeks for at least 12 weeks prior to the screening visit 1. Patients with a following past History or concomitant diseases Other Connective tissue disorders which may interfere the efficacy assessment Chronic or recurrent infectious disease Demyelinating disease Congestive heart failure lymphoproliferative disorder or myelodysplastic syndrome Malignancy Interstitial lung disease 2. Patients with active or latent tuberculosis or history of tuberculosis</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>